Retatrutide 2381089-83-2

Retatrutide 2381089-83yog ib qho tshiab hluavtaws peptide thiab thawj triple agonist nkag mus rau kev kho mob kev loj hlob uas ib txhij lub hom phiaj ntawm glucagon receptor (GCGR), cov piam thaj -dependent insulinotropic polypeptide receptor (GIPR), thiab glucagon{1}}zoo li peptide-1 receptor (GLPR) {6}. Los ntawm kev sib koom ua ke tswj hwm lub zog metabolism thiab cov chaw qab los noj mov, nws tau pom qhov poob phaus thiab glycemic tswj cov teebmeem hauv kev tshawb fawb soj ntsuam uas deb tshaj cov uas twb muaj lawm - phiaj lossis dual - cov tshuaj noj. Los ntawm fatty acid hloov kho tshuab, cov molecule no ua rau ib zaug - noj txhua lub lim tiam; cov ntaub ntawv los ntawm nws qhov kev sim tshuaj Phase III qhia tau hais tias cov kev kawm hauv qib siab - pawg koob tshuaj tau ua tiav qhov hnyav txo qis dua 16%, nrog rau kev txhim kho tseem ceeb hauv hepatic steatosis thiab cardiometabolic cov cim. Nws yog tam sim no suav hais tias yog ib qho ntawm cov neeg sib tw ua yeeb yam zoo tshaj plaws rau kev kho mob ntawm cov kab mob metabolic xws li rog rog, ntshav qab zib hom 2, thiab kab mob tsis muaj dej cawv fatty siab.

1. Kev Txhim Kho Kev Siv Tshuaj
Tam sim no, daim foos thawj zaug rau Retatrutide 2381089-83-2 yog kev txhaj tshuaj subcutaneous. Qhov no yog vim hais tias cov tshuaj peptide tuaj yeem ua rau degradation nyob rau hauv lub plab zom mov tom qab noj qhov ncauj; txoj kev txhaj tshuaj kom ntseeg tau tias cov tshuaj nkag mus rau hauv cov hlab ntsha tsis zoo. Cov khoom txhaj tshuaj feem ntau yog muab los ua cov hmoov lyophilized sterile, uas yog reconstituted nrog ib tug hnyav hnyav tam sim ntawd ua ntej kev tswj hwm.

Raws li qhov tshwm sim, cov kws tshawb fawb tab tom tshawb nrhiav qhov ua tau ntawm kev tsim kho qhov ncauj. Los ntawm kev siv cov thev naus laus zis tshwj xeeb encapsulation lossis suav nrog cov khoom nqus nqus, cov kev siv zog tab tom ua kom cov peptide molecules hla txoj hnyuv thiab nqus mus rau hauv cov hlab ntsha.

2. Kev Siv Tshuaj
Ib qho ntawm lub hom phiaj tseem ceeb tsim rau Retatrutide yog kom txo tau koob tshuaj ntau zaus thiab yog li txhim kho tus neeg mob ua raws. Ua tsaug rau kev hloov pauv molecular uas muaj cov kab mob fatty acid, cov tshuaj muaj peev xwm thim rov qab khi rau albumin hauv cov hlab ntsha, yog li ncua nws lub raum tshem tawm. Kev siv tshuaj noj ua haujlwm hauv kev tshawb fawb soj ntsuam muaj ib zaug - txhaj tshuaj subcutaneous txhua lub lim tiam.

Thaum lub sij hawm thawj theem ntawm kev kho mob, ib tug gradual koob tshuaj escalation tswv yim yog feem ntau siv los txo qhov kev pheej hmoo ntawm kev phiv tshwm sim nyob rau hauv cov neeg mob. Piv txwv li, kev kho mob tuaj yeem pib qis dua, nrog rau qhov ntau npaum li cas tau nce ntxiv txhua ob peb lub lis piam kom txog thaum lub hom phiaj kho tau koob tshuaj. Qhov kev tsim "dose-kev nce ntxiv" no ua rau lub cev maj mam hloov mus rau cov tshuaj, yog li txo qhov tshwm sim ntawm cov teebmeem tshwm sim xws li xeev siab thiab ntuav.

3. Formulation Composition
Txhawm rau kom muaj kev ruaj ntseg ntawm Retatrutide thaum khaws cia thiab tswj hwm, cov hmoov lyophilized feem ntau suav nrog cov khoom siv hauv qab no:

Cov khoom xyaw no lawv tus kheej tsis muaj cov tshuaj pharmacological, tab sis lawv yog cov khoom tseem ceeb rau kev ua kom zoo ntawm cov tshuaj.

4. Solubility yam ntxwv
Lub solubility ntawm Retatrutide sib txawv ntawm cov kuab tshuaj sib txawv; nkag siab txog cov yam ntxwv no pab txhawb kev tsim cov tshuaj formulations:

Hauv kev siv tswv yim, lyophilized hmoov yog feem ntau reconstituted nrog dej rau txhaj tshuaj los yog physiological saline thiab siv tam sim ntawd.

Raws li cov txheej txheem nyuaj, ntev - ua yeeb yam peptide, Retatrutide 2381089-83-2 nthuav tawm cov kev sib tw tseem ceeb txog nws qhov loj - nplai ntau lawm. Lub molecule muaj tag nrho ntev ntawm 39 amino acids thiab nta ib tug tshwj xeeb fatty acid sab - saw hloov, yog li imposing tej yam kev cai ntawm kev loj hlob ntawm nws synthesis txheej txheem. Tam sim no, txoj kev tsim khoom siv dav dav siv cov khoom siv -theem peptide synthesis technology; Txoj kev no suav nrog kev sib txuas ua ke ntawm cov amino acids ua ntej-los yog ua ntej sib sau ua ke peptide fragments-tom qab los ntawm kev sib cais thiab kev ua kom huv kom ua tiav cov khoom kawg.

Nyob rau hauv cov nqe lus ntawm ntau lawm scale, manufacturing peev xwm rau Retatrutide yog expanding sai heev. Tam sim no peb tau tsim ib txoj kab ntau lawm uas muaj peev xwm ua tiav batch yields tshaj li kilogram.

Hais txog txoj hauv kev, cov ntaub ntawv luam tawm patent qhia tau hais tias kev siv lub tswv yim hluavtaws siv ua ntej - tiv thaiv peptide fragments tuaj yeem ua rau luv luv ntau lawm, txhim kho tag nrho cov txiaj ntsig, thiab txo cov kua dej pov tseg, yog li pab txhawb kev ua tiav ntawm kev tsim khoom loj -. Thaum lub sij hawm tsim cov txheej txheem, Rink Amide resin feem ntau yog xaiv raws li cov khoom siv -theem kev txhawb nqa, nrog rau qib hloov pauv tswj nyob rau hauv thaj tsam ntawm 0.3–1.2 mmol / g thiab tus ntoo khaub lig- txuas qib ntawm 1–2%.

Qhov tseem ceeb, kev nthuav dav ntawm cov nplai ntau lawm thiab kev kho kom zoo ntawm cov txheej txheem zoo yog kev sib koom ua ke. Tam sim no, qee lub tuam txhab tau tsim cov txheej txheem tsim khoom hauv kev ua raws li GMP tus qauv ntawm Tuam Tshoj NMPA thiab US FDA, thiab tau pib xa cov ntaub ntawv Tshuaj Master (DMFs). Cov hauv paus ntsiab lus no tau tsim lub hauv paus ruaj khov ntawm kev tsim muaj peev xwm rau Retatrutide txoj kev hloov pauv los ntawm kev tshawb fawb thiab kev txhim kho cov cuab yeej mus rau kev lag luam tshuaj active ingredient.